Sourasky Medical Center (Ichilov)
No hidden fees – just official clinic prices. Pay at the clinic for Hemolytic Anemia treatment and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Hemolytic Anemia treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Hemolytic Anemia treatment journey.
Dr. Amos Toren is a pediatric hemato-oncologist at Sheba Medical Center. He served as Director of the Pediatric Hemato-Oncology and Bone Marrow Transplant Division. Dr. Toren holds a PhD in Human Genetics. He specializes in CAR T-cell therapy and bone marrow transplantation for children. Forbes Israel has recognized his expertise in hematology.
Dr. Hana Golan heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation Division at Sheba Medical Center. She specializes in high-risk pediatric tumors and complex childhood cancers. Dr. Golan serves as the principal investigator for the High-Risk Neuroblastoma ESIOP protocol. She practices at a hospital ranked among the global top 10 by Newsweek.
Dr. Abraham Avigdor is the Director of the Institute of Hematology at Sheba Medical Center. He is a global authority on lymphoma, CAR-T therapy, and complex blood cancers. Dr. Avigdor founded the Israeli Lymphoma Working Group. He helps lead a clinic ranked 7th worldwide by Newsweek in 2026.
Dr. Avichai Shimoni is the Director of Bone Marrow Transplantation at Sheba Medical Center. He treats complex blood cancers. He completed a specialized fellowship at the MD Anderson Cancer Center. Dr. Shimoni uses allogeneic and autologous transplants for high-risk patients. He is a professor and Chairman of Hematology at Tel Aviv University.
Tel Aviv Sourasky Medical Center and Sheba Medical Center are top-equipped Israeli hospitals for treating hemolytic anemia. These JCI-accredited tertiary centers provide specialized hematology units. They offer advanced immune-suppressing therapies and plasmapheresis. Both facilities maintain robust blood banks to manage severe crises safely.
Bookimed Expert Insight: Israeli hematology departments offer high-level expertise, but patient volume varies. Sourasky Medical Center treats over 1,800,000 patients annually across its departments. This high volume often results in more streamlined protocols for rare autoimmune cases. When choosing a specialist, look for leaders like Prof. Avichai Shimoni. His diverse background in pediatrics and adult hematology is vital for transition care.
Patient Consensus: Patients note it is important to find centers with active immunotherapy protocols. Many emphasize choosing doctors experienced with rituximab rather than rushing into a splenectomy.
Israeli hematologists identify hemolytic anemia types using a structured combination of laboratorial, morphological, and molecular techniques. Specialists employ direct antiglobulin testing (DAT) and flow cytometry to differentiate immune-mediated causes. Advanced centers use hemoglobin electrophoresis and next-generation sequencing for definitive hereditary diagnosis within JCI-accredited facilities.
Bookimed Expert Insight: Israeli hematology centers often use flow cytometry and PET/CT imaging as integrated prognostic tools for complex blood disorders. For example, Dr. Abraham Avigdor at Sheba Medical Center uses PET/CT to monitor treatment response. This allows doctors to adjust therapies faster than standard blood work alone might suggest. Choosing a center with these combined capabilities ensures more precise long-term management.
Patient Consensus: Patients note that standard tests can miss rare variants. They recommend requesting genetic panels for genes like PKLR or SPTA1 early in the process. Many patients find that centers with advanced flow cytometry expertise provide much faster results for specific typing.
Advanced hemolytic anemia protocols in Israel integrate monoclonal antibodies and cellular therapies within JCI-accredited facilities. Specialized hematology units employ rituximab and complement inhibitors to target autoimmune destruction. Curative options include allogeneic stem cell transplantation. Automated plasma exchange provides urgent stabilization for refractory cases.
Bookimed Expert Insight: Israeli hematology leadership is defined by academic depth. Both Dr. Abraham Avigdor and Dr. Avichai Shimoni at Sheba Medical Center possess over 30+ years of experience. This expertise is a byproduct of high patient volumes. Sourasky Medical Center treats over 400,000 patients every year. These physicians don't just follow protocols. They actively author them. Dr. Avigdor has published 130+ scientific works. Dr. Shimoni has authored over 250+. For patients, this means access to research-grade diagnostics like PET/CT and experimental trials often before they reach other regions.
Patient Consensus: Patients emphasize the importance of early genetic testing to identify specific sub-types before starting steroid treatment. Many note that combining rituximab with intravenous immunoglobulin (IVIG) serves as an effective bridge therapy while waiting for long-term remission.
International patients can access clinical trials for refractory Autoimmune Hemolytic Anemia (AIHA). Eligibility depends on trial design and country-specific laws. Israeli centers often participate in global multicenter trials. Participation requires meeting strict inclusion criteria. Documented failure of standard therapies is necessary.
Bookimed Expert Insight: Israeli specialists like Dr. Hana Golan and Dr. Amos Toren serve as primary investigators for international trials. Data shows these academic headers bridge trials with compassionate use programs. If trial criteria exclude you, these experts often facilitate off-label access to newer drugs like fostamatinib.
Patient Consensus: Patients note that traveling for trials requires significant self-funding and private medical referrals. Many prioritize seeking compassionate use access to advanced therapies when formal trial residency requirements are too strict.